anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Unopened vials of BUSULFEX must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Discard unused portion.

BUSULFEX diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time.

BUSULFEX diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time.

BUSULFEX is a cytotoxic drug. Follow applicable special handling and disposal procedures1.
In this arm participants will attend the same 3 study visits to complete study questionnaires and assessments. Participants will be asked to wear an acitvity monitor and record an activity diary for one week after the study visits. In between baseline and 6 month follow up, intervention arm participants will receive study physiotherapy. This will consist of an individual assessment and 4 additional sessions of physiotherapy.
The present invention relates to the detection and treatment of caries and microcavities using nanoparticles. Compositions, such as nanoparticles, for detecting and/or treating one or more active caries lesions or microcavities in a subject's teeth are provided. The component or nanoparticle may comprise a biocompatible and biodegradable polymer (e.g., starch) having at least one cationic region and/or having a net positive charge and thus capable of associating with one or more active and/or early carious lesions on teeth in the oral cavity of a subject. The component or nanoparticles are optionally water-soluble or water-dispersible. The component or nanoparticle further comprises an imaging agent (e.g., a fluorophore or dye) bonded to the polymer. Thus, when the component or nanoparticle is associated with one or more active caries lesions, the component or nanoparticle is capable of indicating the presence of the one or more active caries lesions. Also provided are oral care compositions comprising such compounds/nanoparticles and methods of making and using the same.
Rectal cancer (RC) is the third most frequently diagnosed cancer worldwide, and the status of its circumferential resection margin (CRM) is of paramount significance for treatment strategies and prognosis. CRM involvement is defined as tumor touching or within 1 mm from the outermost part of tumor or outer border of the mesorectal or lymph node deposits to the resection margin. The incidence of involved CRM varied from 5.4 % to 36 %, which may associate with an in consistent definition of CRM, the quality of surgeries, and the different examination modalities. Although T and N status are essential factors in determining whether a patient should receive neoadjuvant therapy before surgery, CRM status is a powerful predictor of local and distant recurrence as well as survival rate. This review explores the significance of CRM, the various assessment methods, and the role of magnetic resonance imaging (MRI) and artificial intelligence-based MRI in predicting CRM status. MRI showed potential advantage in predicting CRM status with a high sensitivity and specificity compared to computed tomography (CT). We also discuss MRI advancements in RC imaging, including conventional MRI with body coil, high-resolution MRI with phased-array coil, and endorectal MRI. Along with a discussion of artificial intelligence-based MRI techniques to predict the CRM status of RCs before and after treatments.
Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
In this trial of children ages 6-12, children and their households will receive an intensive home kitchen ventilation intervention after one week of baseline data collection. The intervention includes education regarding improving ventilation in their homes during cooking and replacement of their range hood if it has inadequate flow or an intolerable noise level. During baseline data collection periods the households will be encouraged to continue their regular cooking patterns. The investigators will measure home particulate matter \<2.5 microns (PM2.5) and nitrogen dioxide (NO2) levels for one week at baseline, and a final week after all remaining families receive the cooking ventilation intervention, to assess for changes within each household. The investigators will also examine changes in airways inflammation (as measured by the exhaled fraction of nitric oxide, FeNO), lung function (as measured by spirometry), and reported symptoms after the baseline and intervention period. Members of the research team have successfully conducted youth participatory action research in the low-income, high asthma prevalence community of Richmond, California (CA) as well as extensive youth participatory action research on other environmental health concerns in the low income city of Salinas, CA; using a similar model, the investigators aim to teach research methods to a new group of Richmond youth.
A set of cationic amphiphilic self-assembled peptides (CASPs) is presented that employ high-charge density at fiber edges to disrupt bacterial membranes. CASP nanofibers are effective against  Pseudomonas  biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure.
Cervical cancer (CC) remains among the most frequent cancers worldwide despite advances in screening and the development of vaccines against human papillomavirus (HPV), involved in virtually all cases of CC. In mid-income countries, a substantial proportion of the cases are diagnosed in advanced stages, and around 40% of them are diagnosed in women under 49 years, just below the global median age. This suggests that members of this age group share common risk factors, such as chronic inflammation. In this work, we studied samples from 46 patients below 45 years old, searching for a miRNA profile regulating cancer pathways. We found 615 differentially expressed miRNAs between tumor samples and healthy tissues. Through bioinformatic analysis, we found that several of them targeted elements of the JAK/STAT pathway and other inflammation-related pathways. We validated the interactions of miR-30a and miR-34c with JAK1 and STAT3, respectively, through dual-luciferase and expression assays in cervical carcinoma-derived cell lines. Finally, through knockdown experiments, we observed that these miRNAs decreased viability and promoted proliferation in HeLa cells. This work contributes to understanding the mechanisms through which HPV regulates inflammation, in addition to its canonical oncogenic function, and brings attention to the JAK/STAT signaling pathway as a possible diagnostic marker for CC patients younger than 45 years. To our knowledge to date, there has been no previous description of a panel of miRNAs or even ncRNAs in young women with locally advanced cervical cancer.
Acquired brain injury (ABI) means brain damage caused by events after birth, rather than as part of a genetic or congenital disorders. Those with ABI suffer from cognitive, physical, or behavioral impairments limiting their activity and participation in society. ABI results from traumatic or non-traumatic brain injury due to internal or external source (e.g. infection, brain tumor, hypoxia). Preclinical studies regarding cell therapy in animal models of ABI showed improvements of neurological dysfunction. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for patients with ABI.
BACKGROUND: Despite advances in prevention and treatment, postoperative atrial fibrillation (POAF) is the most common type of complication undergoing cardiac surgery. This study aimed to identify the relationship between POAF and clinical outcomes after coronary artery bypass graft.
METHODS: In this cross-sectional study, we retrospectively reviewed the medical records of 324 patients who had undergone coronary artery bypass grafting in an intensive care unit between 2010 and 2019 at a tertiary hospital in Korea. Propensity score matching was used to estimate a 1:1 match (without: with POAF) using seven covariates to overcome selection bias. Kaplan-Meier survival analysis and Cox proportional hazards modeling were performed to determine the effect on intensive care unit readmission and length of hospital stay.
RESULTS: After controlling for covariates, 1:1 matching was performed for 91 patients in each group. The occurrence of postoperative atrial fibrillation was found to increase the probability of readmission to the intensive care unit, with a 23% reduced probability of readmission for every 10% increase in left ventricular ejection fraction. Multivariate analysis indicated that postoperative atrial fibrillation, chronic obstructive pulmonary disease as a comorbidity, and preoperative hemoglobin were factors affecting the length of hospitalization after surgery. The Kaplan-Meier survival analysis results indicated that the without POAF group had a higher survival rate than the with POAF group.
CONCLUSIONS: Healthcare professionals should recognize negative factors such as postoperative atrial fibrillation and abnormal hematologic parameters that impact major clinical outcomes in patients and may require closer monitoring before and after coronary artery bypass grafting.
The present invention relates to synthetic catalytic DNA molecules or DNAzymes which specifically cleave the RNA sequences of the Japanese Encephalitis Viral genome and is useful in treating Japanese Encephalitis infection. The DNAzyme comprises of a chemical modification, a catalytic domain and two hybridizing arms. The DNAzymes are 29-45 nucleotides in length. The 3' end of the DNAzyme is tethered to a poly-(G)10 tail and the molecule comprises of at least one chemical modification. The chemical modifications are in the form of sugar modification, nucleic acid base modification, and/or phosphate backbone modification. The catalytic DNA molecule inhibits JEV replication in vitro in cultured cells and in vivo in the mouse brain. The present invention also relates to the method of treatment of Japanese encephalitis comprising the steps of introducing the catalytic DNA molecule or DNAzyme into the infected cells under conditions suitable for cleavage and reduction of viral titres.
An object is to reduce the occurrence of aggregation of an inorganic pigment that roughens the texture and dulls the color of a cosmetic containing the inorganic pigment. Porous pigment particles are provided which include cellulose or a cellulose derivative, and an inorganic pigment as main components. Also provided are a method for producing such particles, and a cosmetic containing such porous pigment particles. The particles are resistant to aggregation and are excellently dispersed in a base material to impart a color while improving the dullness problem. The particles of the present invention are porous particles that contain cellulose and have a wrinkle-like or fold-like uneven structure on the surface thereof (that is, have an appropriate amount of pores or voids). Thus, the particles of the present invention have soft and comfortable texture and are suitably added to cosmetics that are directly applied to the skin.
This invention provides a clinical method for the regulation of cell cycles in a mammal, such as a human. The method involves determining the status of an individual's cell cycle and administering a clinical treatment to assist in regulating or normalizing the individual's cell cycle. Determining the individual's cell cycle status provides important starting point information. For example, the cell cycle presents a reflection of the status of T lymphocytes in an individual. Furthermore, the starting point information relating to an individual's cell cycle can be used to scientifically and objectively monitor the effects on the individual's cell cycle of clinical treatment. According to the invention, a lysate is prepared from normal propagated cells. If desirable, one or more of the biologically active components of the lysate can be isolated. The lysate (or the biologically active components isolated from the lysate) is clinically administered to assist in regulating the individual's cell cycle. The regulatory effect of the treatment on the individual's cell cycle is preferably objectively measured by subsequently determining the patient's cell cycle. The application of this invention is not limited to a certain category of individuals. Although the description of this invention focusses on the human applications, the method of this invention can be easily extended to any mammal, so that it can also have veterinary uses.
Patients will start unloaded exercise treatment 3 days after surgery. They will remove the plaster 5 times every day to perform range of motion exercises.
A multi-center two phase, double-blind, placebo controlled, randomized prospective study of 130 lung transplant recipients. Patients will be screened and consented prior to transplant. All consented patients will receive IV ganciclovir within 24 hours of transplant for not more than 14 days. Patients will enroll in Phase I of the study is an open label safety and efficacy analysis of three months of oral valganciclovir in adult transplant recipients who are at risk for CMV. After completion of 3 months of open label therapy, patients that meet the criteria for Phase II of the study will be randomized to 9 months of blinded therapy (Placebo/Valgan). Phase II of the study is designed to assess the efficacy of short course sequential IV ganciclovir followed by oral valganciclovir as compared to the extended period of oral valganciclovir prophylaxis in the prevention of CMV disease in at risk lung transplant recipients
The invention discloses a traditional Chinese medicine powder which can effectively treat acnes (whelks). With the traditional Chinese medicine powder, both symptoms and root cause can be treated, and the effect is stable after curing. The traditional Chinese medicine is prepared from the following Chinese medicine materials: 50g of salvia miltiorrhiza, 30g of raw rehmannia rhizome, 30g of licorice roots, 30g of obtuseleaf dock root, and 10g of rhubarb. The traditional Chinese medicine materials are ground into powder. The powder can be encapsulated, and can be directly taken. The powder is taken once before breakfast and once after supper each day, wherein 9g of the powder is taken each time. The medicine provided by the invention is orally taken, and smearing is not required. The medicine is convenient to take, and provides a stable effect after curing. No reoccurrence, blemish, or toxic and side effect is caused.
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment.      Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
The arrangement has a measuring device and an electronic unit retaining a patient that utilizes momentary vital parameter e.g. blood pressure, of an ergometry or training device. The electronic unit assigns and stores attribute data to and with vital parameter-load parameter data sets. The electronic unit characterizes measuring boundary conditions and/or training boundary conditions and/or environment boundary conditions and estimating an additional rating, while correcting the vital parameter-load parameter data sets and comparing other vital parameter-load parameter data sets. The ergometry or training device is selected from of one of treadmill ergometer (1), weight support devices (2, 3), treadle- ergometer (4), whole body ergometer (5), rudder ergometer (6), stair climbing ergometer (7), active eccentric strength training equipment (16), foot press equipment (17) and a concentric passive strength training equipment (18). Independent claims are also included for the following: (1) a method for validating and/or rating and/or correcting and/or comparing vital parameter burden parameter data sets (2) a software comprising an executable program code for executing a method for validating and/or rating and/or correcting and/or comparing vital parameter burden parameter data sets (3) a computer program product comprising an executable program code of a software for executing a method for validating and/or rating and/or correcting and/or comparing vital parameter burden parameter data sets.
NEW MATERIAL:A sesquiterpene shown by formula I (R is group shown by formula II or formula III). EXAMPLE:(6S,7R,8R,9R)-9-Acetoxy-15-hydroxy-8-[(E)-2-methyl-2-butenoylo xy]-14- oxogermono-(4Z,10E)-4(5),10(1),11(13-trieno-12,6alpha-lactone. USE:A drug having anti-inflammatory action and analgesic action. PREPARATION:Dried whole surface part of Siegesbeckia pubesens of the family Compositae is extracted with an organic solvent such as methanol, etc., or water or a mixed solvent of water and the organic solvent at room temperature of at <= the boiling point of the solvent used for 1-6hr, the solvent is removed from the extracted solution to give residue. The residue is partitioned with water and an inert organic solvent such as n-butanol, etc., and further the solvent is removed from a water-insoluble organic solvent layer to give residue. The residue is purified by chromatography using silica gel and fractionated by liquid chromatography to give a compound shown by formula I.
Leukopenia and neutropenia have been reported during treatment with antipsychotic agents, including LYBALVI [see Adverse Reactions (6)]. Agranulocytosis (including fatal cases) has been reported with other agents in this class. 

Possible risk factors for leukopenia and neutropenia include pre-existing low white blood cell count (WBC) or absolute neutrophil count (ANC) and history of drug-induced leukopenia or neutropenia. In patients with a pre-existing low WBC or ANC or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of LYBALVI at the first sign of a clinically significant decline in WBC in the absence of other causative factors. 

Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue LYBALVI in patients with severe neutropenia (absolute neutrophil count <1000/mm3) and follow their WBC until recovery.
Healthy adults will receive 1.2 mg of naloxone hydrochloride injection solution, administered once via a wearable auto-injector, West Pharma SmartDose Generation I system. The respiratory sensing system under study is used to detect slowed breathing for the purpose of triggering the administration of the naloxone.
A composition for coating the hands &c. to protect them from paints, polishes, and other stains, comprises glue, gelatine, gelatine or other gum soluble in water, whiting or other mild abrasive powder, and a fatty oil, preferably with soap or its ingredients, and with or without a gum dissolved in spirit.  The composition is removed by washing with soap and water.  In an example a solution of 4 oz. of glue in 4 oz. of water is boiled with 4 oz. of whiting, 4 oz. of raw linseed oil, 3/4 oz. of soap, 8 oz. of sandarac gum dissolved in methylated spirit, and water to make 20 oz. of the composition.
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
Inflammatory bowel disease (IBD), which includes Crohn's and Ulcerative Colitis, is a chronic and costly disease of unknown etiology that now affects over 3.1 million people in the United States. Patients with IBD suffer from lifelong malnutrition, pain and bleeding with added risks of cancers, obstructions and fistulas. There is no known cure and the incidence continues to grow. While treatments are usually medical IBD patients will undergo at least one major surgery during their lifetime. Patients also have particularly poor surgical outcomes with high rates of post-operative complications. In an attempt to improve the risk profile of patients and decrease complications, preoperative total parenteral nutrition (TPN) has been used to optimize IBD patients for surgery. While this approach has been successful the cost and morbidities of TPN prohibit its generalized application. Practical strategies that improve surgical outcomes for IBD patients are urgently needed. Improving nutritional deficiencies before an operation may be a practical way to improve post-operative outcomes. The oral administration of preoperative immunonutrition, is an alternative method to improve nutritional states and may have utility in IBD patients who have particularly severe nutritional deficiencies because of disease-specific issues in malabsorption, maldigestion and loss of appetite.
The active comparator is bread fortified according to Peruvian national standards \[Riboflavin (0.18 mg), niacin (2.25 mg), thiamine (0.18 mg), folic acid (60ug), iron (4.2 mg)\]. Participants will receive 2 slices of bread a day for 120 days. It is supplied by Panificadora Bimbo del Peru S.A.